Abstract
Cerebellar ataxias are a group of disabling neurological disorders. Patients exhibit a cerebellar syndrome and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the phenotypic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neurotransmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we discuss the drugs under development.
Keywords: Cerebellum, ataxias, dominant, recessive, X-linked, therapy
Current Neuropharmacology
Title: Past, Present and Future Therapeutics for Cerebellar Ataxias
Volume: 8 Issue: 1
Author(s): D. Marmolino and M. Manto
Affiliation:
Keywords: Cerebellum, ataxias, dominant, recessive, X-linked, therapy
Abstract: Cerebellar ataxias are a group of disabling neurological disorders. Patients exhibit a cerebellar syndrome and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the phenotypic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neurotransmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we discuss the drugs under development.
Export Options
About this article
Cite this article as:
Marmolino D. and Manto M., Past, Present and Future Therapeutics for Cerebellar Ataxias, Current Neuropharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157015910790909476
DOI https://dx.doi.org/10.2174/157015910790909476 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Corneal Changes in Diabetes Mellitus
Current Diabetes Reviews Microwave Accelerated Labeling Methods in the Synthesis of Radioligands for Positron Emission Tomography Imaging
Current Radiopharmaceuticals Animal Models for Investigating Benign Essential Blepharospasm
Current Neuropharmacology The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews Mechanisms Involved in Neuroprotective Effects of Transcranial Magnetic Stimulation
CNS & Neurological Disorders - Drug Targets Experimental Developments and Review of Recent Patents for the Repair of Skeletal Muscles by Methods of Regenerative Medicine
Recent Patents on Regenerative Medicine One Decade Later: What has Gene Expression Profiling Told us About Neuronal Cell Types, Brain Function and Disease?
Current Genomics Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Current Genomics Recent Progress in Anticonvulsant Drug Research: Strategies for Anticonvulsant Drug Development and Applications of Antiepileptic Drugs for Non-Epileptic Central Nervous System Disorders
Current Topics in Medicinal Chemistry Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Development of a Nasal Donepezil-loaded Microemulsion for the Treatment of Alzheimer’s Disease: in vitro and ex vivo Characterization
CNS & Neurological Disorders - Drug Targets Antibiotics and Non-Steroidal Anti-Inflammatory Drugs in Outpatient Practice: Indications and Unwanted Effects in a Gastroenterological Setting
Current Drug Safety Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors
Current Medicinal Chemistry Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry Antimalarial Drug: From its Development to Deface
Current Drug Discovery Technologies Searching for Therapeutics Against Botulinum Neurotoxins: A True Challenge for Drug Discovery
Current Topics in Medicinal Chemistry The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry In Vivo Experimental Models of Epilepsy
Central Nervous System Agents in Medicinal Chemistry